English

RLS Global AB (publ) Interim Report, Q1, 2023

Report this content

JANUARY 1st – MARCH 31st (Previous year in brackets)

  • Net sales amounted to TSEK 89 (TSEK 305)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3)
  • Earnings per share after dilution at SEK -0,09 (SEK 0,07)
  • Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730)
  • Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7)
  • Equity ratio was 82 % (77 %) 

 

Summary of events during FIRST quarter

  • An extra AGM was held 9 February.
  • Lars Johansson was elected Board Member and Chairman of the Board at the extra AGM.
  • Wounds UK publishes the peer-reviewed article “The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel”. The article concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity, in vitro, compared to other debridement products and techniques.

 

Summary of events after FIRST quarteR

  • The UK MHRA (Medicines & Healthcare products Regulatory Agency) has approved RLS’ application to extend the current clinical study for pressure ulcers to UK.
  • Eva Jagenheim leaves her role as CFO in RLS Global AB. She will remain in service during her notice period, at latest to October, to ensure a smooth transition to her successor.

 

 

The Interim Report Q1, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/

Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on May 31st 2023.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25

Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company’s platform technology and its unique features will help many patients around the world. Read more at rls.global

Subscribe

Documents & Links